RhoA/ROCK signalling pathway activation appears to affect a range of processes involved in the pathogenesis of AD, including tau hyperphosphorylation, Aβ aggregation, neuroinflammation, and synaptic damage, promoting neurodegeneration [109–112]. This evidence concerns the gene MAPT and Alzheimer disease.